In the past decade the field of hematopoietic stem cell transplantation has entered a new era with the introduction of reduced intensity conditioning (RIC) regimens. The impact of RIC on the incidence of chronic graft-versus-host disease (GVHD) has not been evaluated systematically. Factors confounding such analyses include short follow-up in studies, absence of prospective comparison trials, use of a variety of RIC regimens, lack of uniform GVHD prophylaxis and lack of rigorous criteria for the diagnosis and staging of chronic GVHD. This review discusses factors that appear to influence the incidence and clinical presentation of chronic GVHD in the RIC transplantation era. Overall, RIC seems to decrease the incidence and severity of acute GVHD through day 100 posttransplant when compared to conventional conditioning; however, there is little evidence to suggest that chronic GVHD is reduced after RIC. For the more definitive assessments of chronic GVHD after RIC it will be important to study this question in prospective comparison trials with long duration of follow-up. The recent National Institutes of Health chronic GVHD consensus project recommendations provide now the critically needed standardized guidelines for the diagnosis, classification and staging of chronic GVHD.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) was initially developed as a method of hematopoietic rescue after intense marrow ablation for a variety of diseases. The key observation that led to the emergence of reduced-intensity conditioning (RIC) for allogeneic HSCT was the discovery of the immune-mediated allogeneic graft-versus-tumor (GVT) effect. 1 RIC allogeneic transplants are now readily performed in patients who would not be able to tolerate conventional high-dose treatment regimens, such as those who are older or who have decreased organ function or performance status. 2 Although rigorous in vivo and ex vivo allograft T-cell depletion techniques that are available today can effectively prevent acute graftversus-host disease (GVHD) and reduce chronic GVHD, T-cell depletion in the absence of other interventions is associated with increased malignancy relapse; as such, a great deal of effort has been placed on identifying strategies that might separate GVT effects from GVHD. 3 One key element that characterizes engraftment in RIC transplantation is the dynamic balance between the host immune system reacting in the direction of the donor (host-versus-graft (HVG)) and the donor immune cells reacting in the direction of the host (graft-versus-host (GVH)). In contrast to the rapid and complete donor hematopoietic chimerism typical of myeloablative transplantation, RIC transplants usually result in a transient state of mixed hematopoietic chimerism. Slow achievement of engraftment after RIC is a relatively important issue as it may affect the dynamics of the development of GVHD and GVL effects. These competing immune reactions are in general T cell-mediated and represent 'mirror images' of one another; 4 in murine models, it has been clearly demonstrated that host T cells inhibit the GVHD potential of donor T-cell inocula. 5 In HLA-matched transplants, the primary targets of these HVG and GVH reactions are minor histocompatibility antigens on the lymphohematopoietic and other tissues, which are also significant targets of the beneficial GVT effect. 6 The goal of this review is to discuss the theories and evidence for the impact of reduced-intensity conditioning transplantation on the incidence and clinical presentation of chronic GVHD.
Pathophysiology of chronic GVHD
Chronic GVHD remains a major complication of allogeneic HSCT, as it affects nearly 50% of long-term transplant survivors and can be life threatening in 20-40% of affected patients. 7, 8 Chronic GVHD is a complex clinical entity with protean manifestations, mimicking multiorgan autoimmune diseases. The pathophysiologic processes in the evolution of chronic GVHD are poorly understood.
Role of inflammation
Murine models have shown that intensive conditioning regimens result in the release of proinflammatory cytokines and the alteration of ligands expressed on the surface of host antigen-presenting cells. 9 This is followed by T-cell ligation and co-stimulation, T-cell expansion, homing of the alloreactive T-cells to various target organs, recruitment of other hosteffector cells (neutrophils, monocytes and natural killer cells), destruction of host tissues including the thymus, by immune effector molecules such as IFN-g, TNF-a, fas-ligand, perforin and granzyme. The resulting thymic dysregulation is proposed to be the key underlying defect in the pathogenesis of chronic GVHD. [10] [11] [12] However, it is important to recognize that most animal models do not replicate the clinical scenario, as frequently chronic GVHD in humans is generated de novo without an antecedent acute GVHD interval. 13 Also there is little evidence in the clinical setting that the inflammation from a preparative regimen is the main predisposing factor for acute or chronic GVHD.
Role of alloreactivity
In fact, the most important predisposing factors to the development of GVHD are the degree of alloreactivity and the kinetics of alloengraftment.
14 For example, some attempts to reduce inflammatory cytokines such as IL-1a after intensive conditioning did not reduce GVHD in a randomized clinical trial. 15 Furthermore, in RIC protocols that result in rapid and complete donor engraftment, acute GVHD incidence and severity is similar to that observed after myeloablative regimens. [16] [17] [18] In one study, it was demonstrated that subjects with acute gut GVHD after RIC had elevated monocyte production of TNF-a. 19 As such, it is possible that the pro-inflammatory cytokine state after transplantation in humans is more a reflection of the kinetics of alloengraftment, rather than the specific intensity of the conditioning utilized.
Role of T cell subsets
At least in some cases, murine data support the theory that chronic GVHD is associated with a polarized Th2 state. 20 On the same token, however, it should be noted that Th2 cells can reduce Th1-mediated acute GVHD. 21, 22 Thereby, a Th2 graft engineering strategy may pay dividends with respect to limiting acute GVHD, including thymic damage and indirectly, reducing chronic GVHD. In a phase I clinical trial in the setting of HLAmatched sibling allogeneic HSCT, infusion of ex vivo polarized donor CD4
þ T cells to Th2 phenotype resulted in expansion of Th2 cytokines (IL-4 and IL-10) in post-transplantation T cells without an apparent increase in GVHD. 23 A subset of CD4 þ CD25 þ T cells called regulatory T cells (Tregs), expressing the transcription factor FoxP3 has been under scrutiny in the pathogenesis of chronic GVHD. In murine models, Tregs have been associated with reduced acute GVHD in several studies. [24] [25] [26] More recently, in a de novo murine model of chronic GVHD, Tregs were associated with reduced chronic GVHD. 27 Furthermore, with respect to the current topic of the role of RIC, it should be noted that murine conditioning regimens that preserve Tregs are associated with reduced GVHD, 28 and in another study, reduced chronic GVHD. 29 In addition to these murine data, clinical data exist to support a protective role for Treg cells against clinical GVHD in humans. In an initial study, the presence of increased FoxP3 mRNA correlated with reduced GVHD. 30 More recently, it has been shown that patients with chronic GVHD had fewer CD4 þ CD25 þ T cells and reduced expression of FoxP3, compared to patients without chronic GVHD and healthy individuals. 31 Nonetheless, it should be noted that one study found an increase in Tregs in subjects with chronic GVHD. 32 Incidence of chronic GVHD in the era of reduced-intensity conditioning
The most important risk factor for development of chronic GVHD is the diagnosis of prior acute GVHD. Other important risk factors that can affect the incidence of chronic GVHD are presented in Table 1. 33 Table 2 summarizes outcomes from some of the largest comparison studies of reduced-intensity conditioning transplantation or from selected single-arm trials. In this review, we will focus discussion on the utilization of unmanipulated, T-cell replete grafts in RIC transplantation. We will not discuss the complexities of the potential impact of T-cell depletion therapies such as the use of alemtuzumab 34 or antithymocyte globulin (ATG), 35, 36 or the impact of immunologic manipulations such as donor lymphocyte infusions (DLI). In this report, unless otherwise stated, chronic GVHD is defined using traditional classification -as any GVHD that occurred 100 days after transplantation, 33 with the caveat that the recently described phenomenon of delayed acute GVHD (beyond 100 days after transplantation) is common after RIC and may be misinterpreted as chronic GVHD.
Impact of prior acute GVHD
Couriel et al. 37 noted that patients who underwent RIC matchedrelated sibling transplants had a lower actuarial rate of grade II-IV acute GVHD (12%) compared with the myeloablative group (36%). The cumulative incidence of chronic GVHD at 18 months was also lower in the nonmyeloablative group (14%) compared with the ablative group (40%), especially beyond the first 200 days, and the difference was independent of age, stem cell source and disease risk category. A retrospective comparison study of matched-related donor transplants, well matched for GVHD prophylaxis, also observed a lower incidence of acute GVHD in the RIC group (44% vs 67%, Po0.001) than in the myeloablative conditioning regimen group. 38 In contrast, although the RIC group of patients had a higher incidence of risk factors to develop chronic GVHD, there was no significant difference in the overall incidence of chronic GVHD. Mielcarek et al. 39 showed in a retrospective analysis of 96 patients that the nomyeloablative group of patients had a lower cumulative incidence of acute GVHD (64 vs 85, P ¼ 0.001), but this did not translate into a lower incidence of extensive chronic GVHD (73 vs 71, P ¼ 0.96). Another study by Kim et al. 40 of 104 patients, of whom 79 were evaluable for chronic GVHD, the incidence of overall chronic GVHD (57 vs 71) and extensive chronic GVHD (38 vs 47) in the RIC group and the standard conditioning group was not significantly different. In this analysis, the incidence of grade II-IV acute GVHD was significantly lower in the RIC group of patients than in the standard conditioning group (29 vs 58, P ¼ 0.01). Among 116 patients who were evaluable for chronic GVHD, the 2-year cumulative incidences of overall chronic GVHD (59 vs 68) and extensive chronic GVHD (28 vs 23) in the standard conditioning group and the reduced-intensity conditioning group were not significantly different. In summary, although reduced-intensity conditioning may lower the incidence of acute GVHD at day 100 post-transplant, it does not appear to translate into a substantial decrease in the incidence of chronic GVHD. Abbreviations: CMV, cytomegalovirus; HLA, human leukocyte antigen; GVHD, graft-versus-host disease.
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Age of recipient
It has been well documented that older patients have a greater incidence of acute and chronic GVHD and more regimenrelated toxicities with standard preparative regimens, thereby frequently excluding them from stem cell transplantation trials. 41 With the advent of RIC regimens, older patients with greater disease burden and poorer performance status are being recruited into these trials. A retrospective study in older patients, did not find any difference in the 2-year cumulative incidence of chronic GVHD (48 vs 56, P ¼ 0.64). However, in multivariate analysis, the risk of chronic GVHD was lower following RIC (RR ¼ 0.69, 95% CI 0.51-0.94; P ¼ 0.02). 42 Short follow-up and varying GVHD prophylactic regimens used, limit the interpretation of the results.
Stem cell source
Sources of hematopoietic stem cells investigated in RIC transplantation include most commonly, G-CSF mobilized peripheral blood stem cells, but also bone marrow and cord blood stem cells.
Peripheral blood and bone marrow stem cell transplantation. Peripheral blood stem cells (PBSC) contain approximately 1 log more CD3
þ T cells and 0.5-1. log more CD34 þ cells than the bone marrow. Although this may lead to quicker and more reliable engraftment, especially in the RIC setting, it could also potentially increase the incidence of T cell mediated GVH effects. A recent large meta-analysis by the Stem Cell Trialists' Collaborative Group of nine randomized trials enrolling 1111 adult patients after myeloablative conditioning reported that PBSCT was associated with a significant increase in the development of extensive and overall chronic GVHD. Of importance, in advanced stage hematologic malignancy patients, the increased extensive GVHD risk was associated with decreased relapse rate and improvement in overall and diseasefree survival. 43 No studies have thus far directly compared the influence of different stem cell sources on chronic GVHD incidence after RIC regimens. A study of a unique RIC regimen consisting of pentostatin, extracorporeal photopheresis and reduced-dose TBI, followed by cyclosporine/methotrexate GVHD prophylaxis, reported only a 9% incidence of grade II-IV acute GVHD. 44 Patients received allogeneic transplant from a related donor (n ¼ 44) or a matched unrelated donor (n ¼ 11), and the stem cell source was bone marrow in 53 and peripheral blood stem cells only in two. At a median follow-up of 502 days (range 154-1104 days) chronic GVHD developed in 43%, 12% with extensive and 31% with limited stage.
Cord blood transplantation. Umbilical cord blood (UCB)
collected immediately after birth and cryopreserved has been established as a feasible and effective source of hematopoietic stem cells for transplantation, especially when no sibling donor is available. In addition to the rapid availability of stem cells, UCB transplantation (UCBT) requires about 1 log less cells than BMT as the infused stem cells have a high proliferation index. Moreover, the immaturity of cord blood lymphocytes allows greater 'immune tolerization' possibly allowing less stringent HLA matching requirements that are characteristic of UCBT. Despite the greater HLA disparity, GVHD incidence or severity with UCBT have not been greater following myeloablative conditioning regimens. 45 Interpretation of data from UCBT studies using reduced-intensity conditioning is difficult as conditioning regimens varied between centers or within studies and most studies had limited numbers of patients or duration of follow-up. A large single unit UCBT study in the setting of reduced-intensity conditioning in 129 patients observed a 26% cumulative incidence of chronic GVHD (Miyakoshi S et al. 46 among 43 recipients of UCBT, cumulative incidence of chronic GVHD was 21% (95% CI, 8%, 34%) at 1 year posttransplant, onset was de novo in two patients, quiescent in five, and progressive in one. All patients, except for the single patient with progressive onset, responded to corticosteroids.
CD34
þ stem cell dose. Although the effect of higher CD34 þ stem cell dose in achieving faster engraftment and accelerated neutrophil and platelet recovery is well established, the impact of CD34 þ cell dose on the incidence of chronic GVHD is less well defined and it may depend on the source of stem cells. 47 Few studies have directly addressed the impact of CD34 þ stem cell dose on the incidence of chronic GVHD in the setting of RIC transplantation. A Spanish retrospective analysis after RIC transplantation from related donors found that the CD34 þ cell dose (median of 5.68 Â 10 6 /kg) influenced the development of chronic GVHD, with a cumulative incidence of extensive chronic GVHD of 74 vs 47% (P ¼ 0.02) among patients receiving more than percentile 75 (p75) of CD34 þ cells vs those receiving p75 or fewer cells. 48 Contradictory to these results, a second study of RIC transplantation from related donors found no correlation between a high CD34 þ cell dose and high incidence of chronic GVHD. 49 In addition, Baron et al. 50 also did not find more acute or chronic GVHD after RIC transplantation from unrelated donors in patients who received high doses of CD34 þ cells (median of 6.5 Â 10 6 /kg). It is possible that the Spanish study noted more extensive chronic GVHD owing to the abbreviated methotrexate course (days 1, 3 and 6 only) in the post-transplant immunosuppression protocol.
Hematopoietic chimerism state. Seattle investigators first demonstrated the feasibility of establishing stable mixed hematopoietic chimerism in DLA-identical littermate dogs after sublethal total body irradiation. 51 The frequent, but commonly transient state of mixed hematopoietic chimerism is a hallmark of RIC transplantation in humans. The complexities of mixed chimerism immunology and its impact on major post-transplant outcomes are still very poorly understood. The kinetics of donor cell engraftment may also theoretically influence the development of chronic GVHD. In a murine RIC transplant model, Perruche et al. 52 observed an association between mixed chimerism state, high levels of circulating host autoantibodies, the persistence of host B cells and the appearance of chronic GVHD-like skin lesions in the mice. In an analysis of a clinical trial by Couriel et al.
37 57% of patients in the nonmyeloablative group achieved complete chimerism at day þ 30, as opposed to 89% in the myeloablative group. In this study, the greater incidence of early mixed chimerism in the reduced-intensity conditioning group had a marginally significant effect in reducing the incidence of acute GVHD. Although the study noted a lower chronic GVHD incidence beyond 200 days, the significance of the impact of mixed chimerism on the incidence of chronic GVHD was not reported.
Clinical presentation of chronic GVHD
Although most of the discussion thus far has focused on the impact of a number of factors on the development and incidence of chronic GVHD in the era of RIC hematopoietic stem cell transplantation, various studies have implied that the clinical presentation of chronic GVHD in this era has also been altered. Before attempting to dissect these reports, one needs to be conscious of the poor standardization and reproducibility of the diagnostic criteria for chronic GVHD and the gradation of disease severity, thus complicating comparison between studies. In an attempt to standardize the criteria for diagnosis of chronic GVHD and provide uniformity in describing the extent and severity of disease, the Working Group of the NIH Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD published a consensus document. 53 These new guidelines abandon the classification of GVHD based strictly on the time of onset of disease manifestations after transplantation. According to these recent NIH consensus recommendations, classic acute GVHD manifestations occurring beyond D þ 100 after transplantation, especially during withdrawal of immune suppression are defined as delayed onset of acute GVHD, whereas a syndrome in which diagnostic or distinctive features of chronic GVHD and acute GVHD appear together is now defined as overlap category of chronic GVHD. Diagnosis of chronic GVHD can be now made any time post-transplant if clinical presentation is characteristic. This new conceptualization of GVHD classification recognizes acute and chronic GVHD as biologically continuous processes and should result in better standardization of GVHD clinical studies in the future.
Median time to onset of chronic GVHD
A delay in the median time to onset of acute GVHD after RIC regimens could translate into delayed onset of chronic GVHD features. In the Seattle study by Mielcarek et al., 39 patients undergoing RICT had a delayed initiation of steroid treatment for any GVHD symptoms (3 months vs 0.95 months, Po0.001), suggesting a delayed onset of GVHD in this group. The use of prolonged mycophenolate rather than short-term methotrexate in the nonmyeloablative group may have accounted for this delay. In a large study 38 where both RIC and CST patients received comparable GVHD prophylaxis, median times to the onset of acute and chronic GVHD were significantly delayed in the RIC group (P-values were o0.001 and .05 respectively). The delayed time to onset of GVHD in the RIC setting may be a reflection of the state of mixed chimerism in these patients. However, a group of Italian investigators did not find any difference between patients undergoing RICT and CST with regard to timing of chronic GVHD. The median day of onset of chronic GVHD was 117 in the RIC group and 112 in the CST group. 54 Chronic GVHD disease severity
Surrogates for chronic GVHD severity include degree or number of organ sites affected, pattern of organ involvement (limited or extensive), degree of organ involvement (mild, moderate or severe), natural evolution of disease (progressive or de novo), number of immunosuppressive agents used to treat chronic GVHD, time to withdrawal of immunosuppressive therapy and risk of non-relapse mortality.
In a Spanish study by Perez-Simon et al. 38 although there was a statistically non-significant trend towards a higher risk of chronic GVHD among RIC transplantation patients compared to myeloablative conditioning regimen, this trend was primarily attributed to a higher incidence of limited GVHD (36.1 vs 12.1%), but not of extensive GVHD (63.9 vs 87.9%). 38 Of significance in this study, the risk of continuation of immunosuppressive therapy at 3 years after transplantation was lower with RIC transplantation (35.5 vs 68.8%, P ¼ 0.028). Busca et al. 54 did not report any difference between patients after RIC (N ¼ 29) or conventional conditioning BMT (N ¼ 29) in either the stage of chronic GVHD (limited chronic GVHD: 52 vs 41%, extensive chronic GVHD: 38 vs 41%), the type of onset, or extent of organ involvement by chronic GVHD. 54 While this study also saw no difference between the two transplant arms in the proportions of patients who required steroids, more patients in the RIC transplant arm had refractory or steroid-dependent chronic GVHD requiring second-line treatments. However, the possibility of discontinuation of systemic immunosuppressive therapy at 3 years after diagnosis was similar with chronic GVHD after RIC and after conventional BMT (63 vs 52%, P ¼ 0.7). Miller et al. reported nearly three times as much limited chronic GVHD than extensive (31 vs 12%) disease after a unique RIC regimen consisting of extracorporeal photopheresis, with pentostatin and reduced dose TBI. 44 Although Mielcarek et al. 39 reported a delay in the initiation of steroids in patients undergoing RIC transplantation they were also more likely to withdraw from systemic immunosuppressive therapy at 20 months (34% of RIC and 2% of CST). 39 In summary, it appears that although reduced-intensity conditioning regimens do not appear to decrease the incidence of chronic GVHD, the disease manifestations may be more limited. Moreover, once these patients are on systemic therapy, they may be able to be withdrawn from systemic immunosuppression at least as quickly as patients after CST and possibly earlier.
Survival after chronic GVHD diagnosis
Baron et al. 55 analyzed GVT effects in 322 patients given HLAmatched related or unrelated donor grafts after RIC transplantation and noted higher probability of achieving complete remission in patients who developed clinical extensive chronic GVHD (HR 1.7; P ¼ 0.07). Grade II-IV acute GVHD had no significant impact on the risk of relapse or progression but was associated with increased risk of nonrelapse mortality and decreased probability of progression-free survival. In contrast, extensive chronic GVHD was associated with reduced risk of relapse or progression (HR 0.4; P ¼ 0.006) and increased probability of progression-free survival (P ¼ 0.003). 55 These findings suggest that chronic GVHD may contribute substantially to the success of RIC transplants for malignant disease.
In conventional conditioning transplantation a number of factors predict non-relapse mortality in chronic GVHD patients, including low platelet count, progressive onset, extensive skin involvement, low performance status, hyperbilirubinemia and others. 33 At this time, data are lacking regarding the prognostic factors for non-relapse mortality in patients who developed chronic GVHD after RIC and such studies are needed to guide chronic GVHD treatment strategies and stratification in clinical trials. The new NIH Consensus Guidelines propose a clinical scoring system that describes the extent and severity of chronic GVHD for each organ or site at any given time, taking functional impact into account. This system has been devised for use in clinical trials to assess the extent to which the severity of organ involvement correlates with non-relapse mortality in chronic GVHD patients. 53 
Conclusion and future directions
In conclusion, although studies employing RIC regimens have frequently reduced the overall incidence of acute GVHD as assessed at day þ 100 post-transplant, this has not necessarily translated into a demonstrated reduction in the incidence of chronic GVHD. Acute GVHD symptoms after RIC occur often in a delayed fashion, thereby leading to an overlap syndrome of acute and chronic GVHD which potentially may increase the estimated incidence of chronic GVHD. Chronic GVHD after RIC appears to be frequently limited rather than extensive, and patients may be able to be withdrawn from immunosuppressive therapies at an earlier time period.
Future trials must incorporate prospective designs, standardized ways of data collection and uniform definitions to allow interpretation of and comparison between various studies. In parallel, it is essential to further investigate murine models of chronic GVHD and perform correlative clinical studies to advance our understanding of the biology and treatment of chronic GVHD. This will lead to better utilization of the RIC allogeneic transplantation technology enabling maximal harnessing of the GVT effect while limiting the GVH effect.
